Terns Pharmaceuticals, Inc. (TERN) Stock
TERN has an Alpha Score of 17 out of 100 (poor), computed on Nov 7, 2026 from 1 of 4 sub-scores.
What is TERN's Alpha Score?
How it works →Alpha Score of 17 reflects poor overall profile with weak quality. Based on 1 of 4 signals – score is capped at 50 until remaining data ingests.
Computed from 1 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 7, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are TERN's key statistics?
Key statistics as of Nov 9, 2026
TERN price chart
Powered by TradingViewWhat does Terns Pharmaceuticals, Inc. do?
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for the treatment of oncology and obesity. Its pipeline features TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 clinical trials for chronic myeloid leukemia, a cancer originating in the bone marrow. The company also advances TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability, currently in Phase IIa trials for metabolic dysfunction-associated steatohepatitis. Terns Pharmaceuticals maintains a portfolio of single-agent and combination therapies targeting chronic liver diseases, including programs like an FXR agonist, a VAP-1 inhibitor, and a THR-β agonist. These efforts address significant unmet needs in areas such as non-alcoholic steatohepatitis and other metabolic conditions. Founded in 2017 and headquartered in Foster City, California, Terns Pharmaceuticals plays a key role in advancing innovative therapies within the biotechnology sector, emphasizing differentiated candidates for serious diseases.